Feinstein Institutes Uncover Ancient Reflex Linked to Future Brain Injury Therapies Researchers at Northwell Health’s Feinstein Institutes for Medical Research have uncovered the molecular mechanism behind one of the body’s…
Biocytogen Secures Favorable Court Ruling in Patent Dispute, Reinforcing Confidence in Its RenNano® Technology Platform Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has announced a significant legal victory…
Tenpoint Therapeutics Launches National ‘Friends of the Presbyopians’ Campaign to Raise Awareness of YUVEZZI for Age-Related Near Vision Loss Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company dedicated to…
Genentech’s Enspryng Receives FDA Priority Review for Thyroid Eye Disease, Advancing a Potential New Treatment Option Genentech, a member of the Roche Group, has announced that the U.S. Food and…
Genmab Reports Positive Phase 3 Results for Fixed-Duration Epcoritamab Combination in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Genmab A/S has announced positive topline results from its pivotal Phase 3…
Enhertu Gains EU Approval for Previously Treated HER2-Positive Solid Tumours AstraZeneca and Daiichi Sankyo have announced that the European Commission (EC) has approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for…
Roche Launches AXELIOS 1 Sequencing Platform to Advance Genomics Research with Innovative SBX Technology Roche has announced the commercial launch of AXELIOS 1, a next-generation sequencing platform powered by its…
Merck Expands Access to New HIV Treatment IDVYNSO™ Through Agreement with the ADAP Crisis Task Force Merck, known as MSD outside the United States and Canada, has announced a new…
DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer to Support Continued Global Growth DePuy Synthes, a global leader in orthopaedic technologies and solutions, has announced the appointment of Christina…
SKYRIZI® Gains FDA Approval for Use in Children with Psoriatic Disease AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of…
Novo Nordisk to Showcase New Haemophilia Research and Investigational Denecimig Data at ISTH 2026 Congress Novo Nordisk has announced that it will present an extensive portfolio of new scientific data…
Epicrispr Biotechnologies Reports Promising Phase 1/2 Data Showing Increased Muscle Volume with EPI-321 in Patients with Facioscapulohumeral Muscular Dystrophy Epicrispr Biotechnologies, a clinical-stage biotechnology company focused on developing epigenetic therapies,…